GlassScriptPhysician profile
James T Thomas
NPI 1700845427
$35,263.46
in general payments reported to CMS, 2019-2025
41 companies · $25K in 2025
The $25K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,686 · 2020: $1,453 · 2021: $1,814 · 2022: $1,878 · 2023: $1,702 · 2024: $1,138 · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $24K · Food and Beverage: $3,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $23,583.33 |
| Food and Beverage | $3,849.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $23,603.44 | 2025 | Auryon Laser System 100-120 Vac, Auryon Laser System 100-120 Vac |
| Abbott Laboratories | $1,297.14 | 2019-2025 | Esprit, Coroflow, Gallant |
| Novartis Pharmaceuticals Corporation | $1,167.91 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $953.24 | 2019-2024 | Xarelto |
| Bard Peripheral Vascular, INC. | $892.83 | 2019-2022 | |
| Amgen INC. | $874.37 | 2019-2024 | Repatha |
| Pfizer INC. | $805.46 | 2019-2025 | |
| Shockwave Medical, INC | $803.04 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Avinger INC. | $713.47 | 2020-2023 | Pantheris |
| Merck Sharp & Dohme LLC | $517.26 | 2021-2025 | Verquvo |
| Cardiovascular Systems INC. | $458.05 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $428.18 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $348.69 | 2019-2024 | Farxiga |
| Boston Scientific Corporation | $332.77 | 2019-2025 | Ekosonic, Cds - Mct/Cem Monitoring |
| Astellas Pharma US INC | $331.98 | 2019-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.30 | 2019-2024 | Jardiance |
| Asahi Intecc USA, INC. | $207.04 | 2023-2024 | Asahi Ptca Guide Wire, Peripheral Vascular |
| E.R. Squibb & Sons, L.L.C. | $198.51 | 2019-2024 | Eliquis, Camzyos |
| Nevro Corp. | $161.98 | 2023 | Senza |
| Regeneron Healthcare Solutions, INC. | $114.39 | 2019 | |
| Tactile Systems Technology INC | $111.45 | 2021-2024 | Entre Plus, Flexitouch Plus |
| Terumo Medical Corporation | $78.38 | 2020 | |
| Abiomed | $74.10 | 2022 | |
| Cardinal Health 200 LLC | $73.28 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $55.79 | 2023 | Inpefa |
| Esperion Therapeutics, INC. | $55.19 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $45.68 | 2022-2025 | Lifevest |
| Getinge USA Sales, LLC | $38.39 | 2020 | |
| Silk Road Medical, INC. | $38.32 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Medtronic Vascular, INC. | $31.61 | 2019 | |
| Biotronik INC. | $30.72 | 2022 | |
| Novo Nordisk INC | $28.64 | 2023-2024 | Ozempic, Rybelsus |
| Irhythm Technologies, INC. | $23.89 | 2023 | Zio Xt Patch |
| Amarin Pharma, INC. | $18.22 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $17.93 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $17.82 | 2025 | |
| Teleflex LLC | $17.53 | 2019 | |
| Bridgebio Pharma, INC. | $15.06 | 2025 | Attruby |
| Scpharmaceuticals INC. | $14.18 | 2025 | |
| Mercator Medsystems, INC. | $14.05 | 2019 | |
| Gilead Sciences, INC. | $13.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.